

This presentation is offered for educational purposes only, intended to serve as continuing medical education for health care professionals. The content of the presentation represents the views and opinions of the original creators of such content and does not necessarily represent the views or opinions of Abbott Products Operations AG or its affiliates (“Abbott”). The distribution of this presentation by Abbott, via its appearance on the a:care websites or any other means, does not constitute an endorsement by Abbott of such content. Abbott does not make any representation or warranty with respect to the accuracy, applicability, fitness, or completeness of the presentation content. Your use of any aspect of this presentation is at your own risk. Abbott cannot and does not accept any responsibility or liability for the consequences of any feature or content of the presentation, nor for any medical decision made based upon the educational content contained in the presentation. Downloading for further distribution or any form of reproduction of this presentation is not allowed



a:care

A:CARE CONGRESS

Improving access to self-management support for patients with chronic conditions: digital solutions

Prof. John Piette

Professor of Health Behavior & Health Education & Director of the Center for Managing Chronic Disease at Ann Arbor Michigan, US

Dr. Bernard Vrijens

Professor of Biostatistics & the University of Liege
CEO of AARDEX
Belgium

Prof. Enrique de Madaria

Associate Professor of Gastroenterology, Miguel Hernández University, Elche; Coordinator of the Biliary-Pancreatic Unit at Alicante's University General Hospital. President of the Spanish Association of Gastroenterology, Spain



a:care

Improving Access To Self-management Support For Patients With Chronic Conditions: Digital Solutions


Prof. John Piette

Professor of Health Behavior & Health Education &
Director of the Center for Managing Chronic Disease at Ann
Arbor Michigan, US

A digital solutions can be defined along three dimensions



Sociodemographic population served



Mobile technologies and communication channels



Program goals and functions

Mobile technologies for improving self-care support



Special devices



Smartphones



Automated calls
(IVR)



Text messages
(SMS)



A digital solutions can be defined along three dimensions



Sociodemographic population served



Mobile technologies and communication channels



Program goals and functions



Treatment Adherence





Monitoring



Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome

Chia-shi Wang¹, Jonathan P. Troost², Larry A. Greenbaum¹, Tarak Srivastava³, Kimberly Reidy⁴, Keisha Gibson⁵, Howard Trachtman⁶, John D. Piette⁷, Christine B. Sethna⁸, Kevin Meyers⁹, Katherine M. Dell¹⁰, Cheryl L. Tran¹¹, Suzanne Vento⁶, Krishna Kallem⁹, Emily Herreshoff², Sangeeta Hingorani¹², Kevin Lemley¹³, Gia Oh¹⁴, Elizabeth Brown¹⁵, Jen-Jar Lin¹⁶, Frederick Kaskel⁴ and Debbie S. Gipson²

Introduction: There is limited information on effective disease monitoring for prompt interventions in childhood nephrotic syndrome. We examined the feasibility and effectiveness of a novel text messaging system (SMS) for disease monitoring in a multicenter, prospective study.

1. Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA; 2. Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA; 3. Department of Pediatrics, Children's Mercy Hospital and University of Missouri at Kansas City, Kansas City, Missouri, USA; 4. Department of Pediatrics, Montefiore Medical Center, New York, New York, USA; 5. Department of Medicine and Pediatrics, University of North Carolina, Chapel Hill, North Carolina, USA; 6. Department of Pediatrics, NYU School of Medicine, New York, New York, USA; 7. Department of Health Behavior & Health Education, University of Michigan, Ann Arbor, Michigan, USA; 8. Department of Pediatrics, Cohen Children's Medical Center of New York, New Hyde Park, New York, USA; 9. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 10. Department of Pediatrics, Case Western Reserve University, Cleveland Clinic Children's, Cleveland, Ohio, USA; 11. Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA; 12. Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA; 12. Department of Pediatrics, Children's Hospital-LA, Los Angeles, California, USA; 14. Department of Pediatrics, Stanford University, Palo Alto, California, USA; 15. Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA; and 16. Department of Pediatrics, Wake Forest University, Winston-Salem, North Carolina, USA

Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome





Figure 4: Percentage of patients with nephrotic range proteinuria as captured by short message service (SMS) reporting versus in-person clinic visits

Figure 5: Time to remission after study enrolment by short message service (SMS)- captured urine protein results versus participant reporting during in-person study visits. CR, complete remission

1. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 2. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 3. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 4. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 5. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 6. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 7. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 8. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 9. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 10. Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA; 11. Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA; 12. Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA; 12. Department of Pediatrics, Children's Hospital-LA, Los Angeles, California, USA; 14. Department of Pediatrics, Stanford University, Palo Alto, California, USA; 15. Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA; and 16. Department of Pediatrics, Wake Forest University, Winston-Salem, North Carolina, USA



Lifestyle behaviors




Interventions for weight management using text messaging



Review

A systematic review and meta-analysis of interventions for weight management using text messaging

G. Siopis,¹ T. Chey² & M. Allman-Farinelli¹



Forest plot: mean weight change in body weight of intervention and control participants with the combined meta-regression shown below. Effect size (ES) is indicated by black diamonds; percentage weighting of each study towards the overall effect is indicated by the size of grey squares; 95% confidence interval is indicated by horizontal lines; the overall treatment effect lies at the center of the diamond with left and right endpoints indicating the 95% confidence interval (CI).



Complex behavioral health challenges




Tailored integrative Internet intervention for depression

Research Article

Effectiveness of a tailored, integrative Internet intervention (deprexis) for depression: Updated meta-analysis

Conal Twomey¹, Gary O'Reilly¹,
Oliver Bültmann², Björn Meyer^{2,3,a}



1. School of Psychology, University College Dublin, Belfield, Dublin, Ireland; 2. Research Department, Gaia, Hamburg, Germany; 3. Department of Psychology, City, University of London, London, England, United Kingdom

Interactive Voice Response-Based Self-management for Chronic Back Pain

THE COPES NONINFERIORITY RANDOMIZED TRIAL

Alicia A. Heapy. PhD; Diana M. Higgins. PhD; Joseph L. Goulet. PhD, Kathryn M. LaChapelle, MPH; Mary A. Driscoll. PhD; Rebecca A Czlapski. MA; Eugenia Buta. PhD; John D. Piette, PhD; Sarah L. Krein, PhD; Robert D. Kerns. PhD

IMPORTANCE Recommendations for chronic pain treatment emphasize multimodal approaches, including nonpharmacologic interventions to enhance self-management. Cognitive behavioral therapy (CBT) is an evidence-based treatment that facilitates management of chronic pain and improves outcomes, but access barriers persist. Cognitive behavioral therapy delivery assisted by health technology can obviate the need for in-person visits, but the effectiveness of this alternative to standard therapy is unknown. The Cooperative Pain Education and Self-management (COPES) trial was a randomized, noninferiority trial comparing IVR-CBT to in-person CBT for patients with chronic back pain.

OBJECTIVE To assess the efficacy of interactive voice response-based CBT (IVR-CBT) relative to in-person CBT for chronic back pain.

DESIGN, SETTING, AND PARTICIPANTS We conducted a noninferiority randomized trial in 1 Department of Veterans Affairs (VA) health care system. A total of 125 patients with chronic back pain were equally allocated to IVR-CBT (n = 62) or in-person CBT (n = 63).

INTERVENTIONS Patients treated with IVR-CBT received a self-help manual and weekly prerecorded therapist feedback based on their IVR-reported activity, coping skill practice, and pain outcomes. In-person CBT included weekly, individual CBT sessions with a therapist. Participants in both conditions received IVR monitoring of pain, sleep, activity levels, and pain coping skill practice during treatment.

MAIN OUTCOMES AND MEASURES The primary outcome was change from baseline to 3 months in unblinded patient report of average pain intensity measured by the Numeric Rating Scale (NRS). Secondary outcomes included changes in pain-related interference, physical and emotional functioning, sleep quality, and quality of life at 3, 6, and 9 months. We also examined treatment retention.

Heapy AA, Higgins DM, Goulet JL, LaChapelle KM, Driscoll MA, Czlapski RA, Buta E, Piette JD, Krein SL, Kerns RD. Interactive Voice Response-Based Self-management for Chronic Back Pain: The COPES Noninferiority Randomized Trial. *JAMA Intern Med.* 2017 Jun 1;177(6):765-773.

Interactive Voice Response-Based Self-management for Chronic Back Pain

THE COPEs NC

Alicia A. Heapy, PhD; D
Rebecca A Czlapski, M

IMPORTANCE Recon
enhance self-managem
improves outcomes, but
person visits, but the eff
(COPEs) trial was a ran

OBJECTIVE To assess


DESIGN, SETTING, 2
care system. A total of 1:

INTERVENTIONS Pa
reported activity, coping
in both conditions recei

MAIN OUTCOMES A
pain intensity measured
emotional functioning. s

Heapy AA, Higgins DM, Goul
Chronic Back Pain: The COPEs

NUMBER OF TREATMENT WEEKS BY CONDITION



CBT indicates cognitive behavioural therapy; IVR, interactive voice response.

I. PhD;

macologic interventions to
ment of chronic pain and
obviate the need for in-
and Self-management
ck pain.

hronic back pain.

terans Affairs (VA) health
 (n = 63).

back based on their IVR-
h a therapist. Participants
it.

atient report of average
erference, physical and

ased Self-management for



a:care



Improving Access To Self-management Support For Patients With Chronic Conditions: Digital Solutions


Dr. Bernard Vrijens, PhD

AARDEX Group

Liège University

Honorary Member, ESPACOMP, Belgium

Medication Intake Behavior



YOU CAN'T MANAGE WHAT YOU DON'T MEASURE




Measure

Manage



The Unfortunate 80% Rule!

EACH OF THESE 6 PATIENTS TOOK THE SAME PERCENTAGE (81%) OF PRESCRIBED DOSES, WHICH SOUNDS GOOD, BUT LOOK




The variability in all these cases poses a significant risk to clinical success

Variable adherence creates drug-specific issues of efficacy, safety & drug resistance

What's going on?




Occasional toxicity



Periodic loss of effectiveness & emergence of drug resistance

Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. *Annu Rev Pharmacol Toxicol.* 2012;52:275-301.

Medication Event Monitoring System (MEMS®)



- 


1 million users
- 

70 countries
- 

35 years
- 

800+ Publications

The Scientific Evidence



1. El Alili M, Vrijens B, Demonceau J, Evers SM, Hilgsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. *Br J Clin Pharmacol.* 2016;82(1):268-279. 2. Demonceau J, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. *Drugs.* 2013 May;73(6):545-62.





Empower Patients and Providers



Self-management and patient engagement in care



Facilitate communication between the patient and providers (e.g. shared decision making)



Consistency in the message delivered based on individual measures (e.g. multidisciplinary team)



Individualized care based on data (e.g. rational decision rather than irrational or emotional)



Risk stratification and prevention (e.g. set priorities and optimize providers' time)

Digitally-Enabled Integrated Person-Centred Care¹

BENEFITS FOR ALL STAKEHOLDERS – TIME IS RIPE FOR A CHANGE!



Patients

- Improves quality, safety, and effectiveness of medications
- Greater patient awareness and participation in care



Providers

- Better use of time allocation
- Emergence of new forms of collaboration and multidisciplinary approaches



Payers

- Decrease healthcare expenditures on chronic therapies
- Improve return on Rx spend by improving outcomes and reducing wastage



Industry

- Maximise value of the molecule to sustain high growth
- Improve image, retain patients



a:care

IMPROVING ACCESS TO SELF-MANAGEMENT SUPPORT FOR PATIENTS
WITH CHRONIC CONDITIONS: DIGITAL SOLUTIONS

Lock-down: The Impact Of COVID-19 On Patient Adherence

Prof. Enrique de Madaria

Miguel Hernández University, Elche

Alicante's University General Hospital

President of the Spanish Association of Gastroenterology

Spain

Disclosures

HONORARIA FROM TAKEDA PHARMACEUTICAL COMPANY, ABBOTT AND MYLAN.

COVID-19 pandemic



SINCE DEC 2019 TO SEPT 2021

226,418,202 cases

4,660,390 deaths



KEY FEATURES OF COVID-19


Direct person-to-person respiratory transmission¹

Primary transmission via respiratory particles, hand contamination by secretions¹

Early reports: mild 81%, Severe 14%, critical 5%, 2.3% mortality²

¹ The Lancet Respiratory Medicine. COVID-19 transmission-up in the air. *Lancet Respir Med*. 2020 Dec;8(12):1159. ² Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Apr 7;323(13):1239-1242.

Image from: Johns Hopkins Coronavirus resource center, Sep 16 2021



COVID-19 And Patients With Non-communicable Chronic Diseases

EFFECTS OF THE LOCK DOWN ON RISK FACTORS



Probable increase in habits like caloric/salty food intake, tobacco use, alcohol and cannabis use¹



After an initial decrease, the number of smokers have risen²




Decrease in the effectivity of smoking cessation programs³

1 Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N. Global Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and Substance Use During the Early COVID-19 Containment Phase in the General Population in France: Survey Study. *JMIR Public Health Surveill.* 2020 Sep 18;6(3):e19630. 2 The Lancet Respiratory Medicine. COVID-19, smoking, and cancer: a dangerous liaison. *Lancet Respir Med.* 2021 Sep;9(9):937. 3 Veldhuizen S, Selby P, Wong B, Zawertailo L. Effect of COVID-19 on smoking cessation outcomes in a large primary care treatment programme: an observational study. *BMJ Open.* 2021 Aug 26;11(8):e053075.



Comorbidity and COVID-19

COVID-19 CASE SURVEILLANCE, USA



Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton KE. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jun 19;69(24):759-765.



COVID-19 And Patients Receiving Chronic

DECREASED MEDICAL ADHERENCE?



Fear of patients with comorbidity to have severe disease/ to die



Fear of visiting healthcare facilities, decreased availability for general practitioners, collapse of hospitals -> 40% decline in outpatients visits in USA¹



COVID-19 is perceived as a major health threat, chronic conditions may seem harmless



Economic crisis: decreased incomes, loss of medical insurances



There may be disruption of drug supply chains (8% increase in drug shortages during first quarter of 2020 in USA²)

¹ Ziedan et al, Effects of State COVID-19 Closure Policy on NON-COVID-19 Health Care Utilization, NBER working paper series 2020:1-68 ² Ziedan, J Chem Inf Model 2020

Impact of COVID-19 on noncommunicable disease (NCD) resources and services, WHO survey



75% countries in 2020 with considerable degree of disruption of NCD services

- All regions, all income groups. Higher impact on LMICS



Most countries had disruption in essential services for hypertension, diabetes and cancer




Main reasons:

- Decrease in inpatient volume due to the cancellation of elective care
- Closure of population-level screening programs and outpatient disease-specific clinics
- Lockdowns
- Impacts on staffing
- Insufficient personal protective equipment (PPE)

Retrospective analysis on a dataset of 9.4 billion US prescription drug claims from 252 million patients from May 2019 through August 2020

LIKELIHOOD OF DISCONTINUING DRUG



Clement J, Jacobi M, Greenwood BN. Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims. *PLoS One*. 2021 Apr 1;16(4):e0249453.




COVID-19, medical adherence and low-and middle-income countries (LMICS)



High disease burden: chronic infectious and non-communicable diseases¹

- HIV/AIDS, tuberculosis, hepatitis, diabetes, cardiovascular diseases, cancers, chronic pulmonary diseases and mental illnesses²



LMICs often rely heavily on drug imports, COVID-19 global shut down




Lower access to technology but 40% LMICS countries used telemedicine during COVID-19 crisis in 2020³

1 Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. *Res Social Adm Pharm.* 2021 Jan;17(1):2023-2026. 2 Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. *Trans R Soc Trop Med Hyg.* 2006 Mar;100(3):191-9. 3 WHO 2020, The impact of the covid-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment <https://www.who.int/publications/i/item/9789240010291> [Accessed October 2021]

European Network to Advance Best practices & technology on medication adherence (ENABLE) cross-sectional study


AVAILABILITY OF VARIOUS FORMS OF TELECONSULTATION




Ágh T, van Boven JF, Wettermark B, Menditto E, Pinnock H, Tsiligianni I, Petrova G, Potočnjak I, Kamberi F, Kardas P. A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. *Front Pharmacol.* 2021 Jun 7;12:685696.

European Network to Advance Best practices & technology on medication adherence (ENABLE) cross-sectional study

AVAILABILITY OF OPTIONS FOR REQUESTING CHRONIC MEDICATION PRESCRIPTIONS



Ágh T, van Boven JF, Wettermark B, Menditto E, Pinnock H, Tsiligianni I, Petrova G, Potočnjak I, Kamberi F, Kardas P. A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. *Front Pharmacol.* 2021 Jun 7;12:685696.



Example: Pancreatic Enzyme Replacement Therapy (PERT)



Pancreatic juice is needed for adequate digestion of food, particularly fats



Many pancreas diseases/ conditions associated to Pancreatic Exocrine Insufficiency

- Chronic pancreatitis
- Acute pancreatitis
- Pancreatic cancer
- Cystic fibrosis
- Pancreatic surgery
- Celiac disease



PEI is managed with oral pancreatic enzymes, a chronic treatment



Low adherence presumably associated to malnutrition and poorer outcomes²

1. Brennan GT, Saif MW. Pancreatic Enzyme Replacement Therapy: A Concise Review. *JOP*. 2019;20(5):121-125. *Epub* 2019 Jul 30. 2. Trapnell BC, Chen S, Khurmi R, Bodhani A, Kapoor M, Haupt M. Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy. *Chron Respir Dis*. 2020 Jan-Dec;17:1479973119900612.

PERTCOVID SURVEY



PERTCOVID survey



Patients with PEI receiving PERT



Impact of COVID-19 on adherence



**Gastroenterology Department, Alicante's Univ.
Gen. Hospital & Psychology Department, Miguel
Hernandez University, Alicante, Spain**



Phases of development


- June 2021: initial interviews of psychologist team with a small sample of patients (5)
- July 2021: first draft of the survey
- August 2021: initial tests with small sample of patients (4) for validation
- September 2021: final data acquisition

PERTCOVID SURVEY – conducted by Alicante's Univ. Gen. Hospital, preliminary results.

PERTCOVID Survey

50 PATIENTS UNDER PERT, 92% CHRONIC PANCREATITIS, 4% ACUTE PANCREATITIS, 2% PANCREATIC CANCER, 2% PANCREATIC SURGERY

0: Never, 1: Seldom, 3: Sometimes, 4: Often, 5: Always




PERTCOVID Survey

50 PATIENTS UNDER PERT, 92% CHRONIC PANCREATITIS, 4% ACUTE PANCREATITIS, 2% PANCREATIC CANCER, 2% PANCREATIC SURGERY

0: no association, 10: absolute association

$p=0.8$



CONCLUSIONS

- The pandemic seems to be associated **with increase in** unhealthy habits
- Risk factors for decreased medical adherence: fear of visiting healthcare facilities + decreased availability, decreased awareness about the importance of chronic diseases, economic crisis, disruption of drug supply chains
- More important impact of the pandemic in low-and middle-income countries
- Digital tools are important to fight against decreased medical adherence in this scenario

